Clinical cure strategy for hepatitis B: immunomodulatory therapy
10.3760/cma.j.cn501113-20200722-00410
- VernacularTitle:乙型肝炎临床治愈策略：抗病毒药物与免疫调节治疗
- Author:
Qing XIE
1
;
Qin NING
;
Guiqiang WANG
;
Chengwei CHEN
;
Fusheng WANG
Author Information
1. 上海交通大学医学院附属瑞金医院感染科 200025
- Keywords:
Hepatitis B, chronic;
Antiviral agents;
Immunotherapy
- From:
Chinese Journal of Hepatology
2020;28(8):644-648
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B virus (HBV) infection remains a major world public health problem. Current guidelines of chronic hepatitis B (CHB) suggest the clinical cure as the ideal thearapeutic goal. Although the optimization of the existing antiviral treatment can make some patients achieve clinical cure, but for most patients with chronic hepatitis B, it is difficult to achieve clinical cure according to the existing antiviral treatment plan. The medical community has begun to work together to seek new treatment strategies, especially the immune intervention measures aimed at restoring the immune response in the liver microenvironment. Notably, immune antiviral response plays a crucial role in HBV clearance, and the clinical cure of chronic hepatitis B is finally achieved through the optimized combination of antiviral and immunomodulatory drugs.
